14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close May 08, 2026
AKRO vs KZR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of May 08, 2026, Kezar Life Sciences, Inc. (KZR) captures the overall head-to-head institutional edge over Akero Therapeutics, Inc. (AKRO) on higher Unified Composite conviction (60.1/100 BUY vs. 60.0/100 BUY) after splitting the core matrix 1–3 (led by Options & Positioning), while AKRO wins 3–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus KZR at $7.29 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: KZR earns the overall head-to-head edge with a stronger Unified Composite Score (60.1/100 BUY vs. AKRO 60.0/100 BUY) and 0.60β · 8% Vol risk profile, whereas AKRO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs KZR. Trailing 12-month operating profitability (AKRO 0.0% vs KZR 0.0%) and valuation multiples (AKRO N/M vs KZR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $54.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AKRO vs KZR Key Questions & Quantitative Answers
As of May 08, 2026, Kezar Life Sciences, Inc. (KZR) captures the overall head-to-head institutional edge over Akero Therapeutics, Inc. (AKRO) on higher Unified Composite conviction (60.1/100 BUY vs. 60.0/100 BUY) after splitting the core matrix 1–3 (led by Options & Positioning), while AKRO wins 3–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus KZR at $7.29 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: KZR earns the overall head-to-head edge with a stronger Unified Composite Score (60.1/100 BUY vs. AKRO 60.0/100 BUY) and 0.60β · 8% Vol risk profile, whereas AKRO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
AKRO leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with KZR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus N/A for KZR. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KZR.
AKRO and KZR trade at balanced relative valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas KZR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus KZR (-59.9% ROE) capital efficiency.
In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, KZR carries 37.2% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.60β · 8% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 08, 2026. For educational research only; not investment advice.